World Journal of Urology

, Volume 36, Issue 4, pp 683–684 | Cite as

Reply to letter to editor regarding: LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer

  • Marcel Cabral Cognette
  • Andreza Vargas da Silva
  • Roberto Dias Machado
  • Eliney Ferreira Faria
Letter to the Editor


  1. 1.
    Vargas A, Machado RD, Filho DI, Paiva CE, Dos Reis RB, Tobias-Machado M et al (2016) LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer. World J Urol 34(12):1621–1628CrossRefPubMedGoogle Scholar
  2. 2.
    Ostergren PB, Klausen TW, Fode M (2017) No convincing evidence on differences in metabolic effects of medical and surgical castration in the treatment of prostate cancer. World J Urol. PubMedGoogle Scholar
  3. 3.
    Timilshina N, Hussain S, Breunis H, Alibhai SM (2011) Predictors of hemoglobin decline in non-metastatic prostate cancer patients on androgen deprivation therapy: a matched cohort study. Support Care Cancer 19(11):1815–1821CrossRefPubMedGoogle Scholar
  4. 4.
    Hara N, Nishiyama T, Takizawa I, Saito T, Kitamura Y, Takahashi K (2010) Decline of the red blood cell count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor-1 and erythropoiesis. Urology. 75(6):1441–1445CrossRefPubMedGoogle Scholar
  5. 5.
    Sun M, Choueiri TK, Hamnvik OP, Preston MA, De Velasco G, Jiang W et al (2016) Comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen-deprivation therapy. JAMA Oncol 2(4):500–507CrossRefPubMedGoogle Scholar
  6. 6.
    Chen DY, See LC, Liu JR, Chuang CK, Pang ST, Hsieh IC et al (2017) Risk of cardiovascular ischemic events after surgical castration and gonadotropin-releasing hormone agonist therapy for prostate cancer: a nationwide cohort study. J Clin Oncol 35(32):3697–3705CrossRefPubMedGoogle Scholar
  7. 7.
    Bayoumi AM, Brown AD, Garber AM (2000) Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 92(21):1731–1739CrossRefPubMedGoogle Scholar
  8. 8.
    Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C et al (1999) Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep/Technol Assess (Summary). 4:i-xGoogle Scholar
  9. 9.

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Marcel Cabral Cognette
    • 1
  • Andreza Vargas da Silva
    • 1
  • Roberto Dias Machado
    • 1
  • Eliney Ferreira Faria
    • 1
  1. 1.Hospital de Cancer de BarretosBarretosBrazil

Personalised recommendations